The Applied Biology & Chemistry Journal (TABCJ)

ISSN: 2582-8789 (online)

Doxorubicin hydrochloride liposome and albumin-bound paclitaxel in cancer: a nanotechnology perspective

Rajib Hossain, Rasel Ahmad Khan, Muhammad Torequl Islam, Divya Jain, Pracheta Janmeda, Obinna Chukwuemeka Godfrey*, Shiwali Bisht & Aakanksha Bharati

Rajib Hossain

Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Dhaka, Bangladesh

Rasel Ahmad Khan

Pharmacy Discipline, Life Science School, Khulna University, Khulna-9280, Bangladesh

Muhammad Torequl Islam

Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Dhaka, Bangladesh

Divya Jain

Department of Bioscience and Biotechnology, Banasthali Vidyapith, Rajasthan-304022, India

Pracheta Janmeda

Department of Bioscience and Biotechnology, Banasthali Vidyapith, Rajasthan-304022, India

Obinna Chukwuemeka Godfrey*

Department of Biochemistry, Faculty of Basic Medical Sciences, Universtiy of Calabar, Calabar-540271, Cross River, Nigeria

https://orcid.org/0000-0002-3868-4028

Shiwali Bisht

Aarogyam Medical College and Hospital, Bhagwanpur, Dehradun-247661, Uttarakhand, India

Aakanksha Bharati

Department of Environmental Sciences, Baba Saheb Bhim Rao Ambedkar University, Lucknow-226025, Uttar Pradesh, India

Abstract

Nanoparticles (1-100 nanometres in size), products of nanotechnology, offer a modern way to transport anti-cancer drugs by acting as transporters of drugs into tumor cells, hence quenching tumor cell proliferation. Such nanoparticles may be formulated to bind to the tumor cell membrane or inhibit specific reactions of tumor biosynthetic pathway by gene repression, or directly bind to the active sites of essential enzymes in the biosynthetic pathway. Consequently, drugs are completely delivered to the desired cancerous cells without system interference. Liposomal doxorubicin and albumin-bound paclitaxel are two examples of nanotechnologically developed drugs for treating cancer. Modern knowledge of nanotechnology opens up new opportunities for innovative research on cancer therapies and administration and helps minimize harm to healthy cells. This review focuses on the doses and routes of administration of these chemotherapeutic agents used in treating cancers.

Keywords

cancer; chemotherapeutics; drug delivery; nanoparticle; nanoparticle formulation; nanotechnology

Cite this article

Hossain R, Khan RA, Islam MT, Jain D, Janmeda P, Godfrey OC, Bisht S, Bharati A (2021). A review on doxorubicin hydrochloride liposome and albumin-bound Paclitaxel chemotherapy with respect to nanotechnology. T. Appl. Biol. Chem. J; 2(2):59-65. https://doi.org/10.52679/tabcj.2021.0010

Citation: 0

References

[1] Poole Jr CP, Owens FJ (2003). Introduction to nanotechnology. John Wiley & Sons Inc.

[2] GlobalData Thematic Research (2020). Nanotechnology in medicine: technology trends. https://www.medicaldevice-network.com/comment/nanotechnology-medicine-technology/ (accessed 6 April 2021).

[3] Koushik OS, Rao YV, Kumar P, Karthikeyan R (2016). Nano drug delivery systems to overcome cancer drug resistance - a review. J Nanomed Nanotech; 7(3):378. [CrossRef]

[4] Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY (2014). Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev; 65(13-14):1866-79. [CrossRef] [PubMed]

[5] Housman G, Byler S, Heerboth S, Lapinska K, et al. (2014). Drug resistance in cancer: an overview. Cancers (Basel); 6(3):1769-92. [CrossRef] [PubMed]

[6] Zargar A, Chang S, Kothari A, Snijders AM, et al. (2019). Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. Chron Diseases Transl Med; 5(4): 258-266. [CrossRef]

[7] Yuan R, Hou Y, Sun W, Yu J, et al. (2017). Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci; 1401(1):19-27. [CrossRef] [PubMed]

[8] Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, et al. (2020). Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Upd; 50:100682. [CrossRef] [PubMed]

[9] Jiang W, Xia J, Xie S, Zou R, et al. (2020). Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of IncRNAs. Drug Resist Upd; 50:100683. [CrossRef] [PubMed]

[10] Polovich M, White JM, Kelleher L (2005). Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (2nd ed.), Oncology Nursing Society, Pittsburg.

[11] Barenholz Y (2012). Doxil® – the first FDA-approved nano-drug: lessons learned. J Control Release;160(2):117–34. [CrossRef] [PubMed]

[12] Doxil (doxorubicin hydrochloride liposome injection), for intravenous use. Initial US approval (1995). https://www.doxil.com/shared/product/doxil/doxil-prescribing-information.pdf/ (accessed 8 November 2016).

[13] Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol;19(14):3312–22. [CrossRef] [PubMed]

[14] O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol; 15(3):440–9. [CrossRef] [PubMed]

[15] Orlowski RZ, Nagler A, Sonneveld P, et al. (2007). Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol; 25(25):3892-901. [CrossRef] [PubMed]

[16] Rxlist (2020). Doxorubicin hydrochloride. https://www.rxlist.com/doxorubicin-hydrochloride-drug.htm (accessed on 20 April 2021).

[17] WebMD (2021). Abraxane-paclitaxel protein bound. https://reference.medscape.com/drug/abraxane-paclitaxel-protein-bound-999775 (accessed 20 April 2021).

[18] Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P (2011). Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother; 23(2):59-66. [CrossRef] [PubMed]

[19] Thapa RK, Byeon JH, Choi HG, Yong CS, Kim JO (2017). PEGylated lipid bilayer-wrapped nano-graphene oxides for synergistic co-delivery of doxorubicin and rapamycin to prevent drug resistance in cancers. Nanotechnology; 28(29): 295101. [CrossRef] [PubMed]

[20] Chowdhury P, Nagesh PK, Kumar S, Jaggi M, Chauhan SC, Yallapu MM (2017). Pluronic nanotechnology for overcoming drug resistance. In: Yan B, Zhou H, Gardea-Torresdey J (Eds) Bioactivity of engineered nanoparticles. Nanomedicine and Nanotoxicology. Springer, Singapore: pp 207-237. [CrossRef]

[21] Garg A, Visht S, Sharma PK, Kumar N (2011). Formulation, characterization, and application on nanoparticles: a review. Der Pharmacia Sinica; 2(2):17-26.

[22] Oake A, Bhatt P, Pathak Y (2019). Understanding surface characteristics of nanoparticles. In: Pathak Y (eds.) Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer, Cham: pp 1-17. [CrossRef]

[23] Panyam J, Labhasetwar V (2003). Biodegradable nanoparticles for drug and gene delivery cells and tissue. Adv Drug Deliv Rev; 55(3):329-47. [CrossRef] [PubMed]

[24] Hernández-Giottonini KY, Rodríguez-Córdova RJ, Gutiérrez-Valenzuela CA, Peñuñuri-Miranda O, Zavala-Rivera P, et al. (2020). PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. RSC Adv; 10(8):4218-31. [CrossRef]

[25] Kumar B, Jalodia K, Kumar P, Gautam HK (2017). Recent advances in nanoparticle-mediated drug delivery. J Drug Deliv Sci Technol; 41:260-268. [CrossRef]

[26] Patel S, Singh D, Srivastava S, Singh M (2017). Nanoparticles as a platform for antimicrobial drug delivery. Adv Pharmacol Pharm; 5(3):31-43. [CrossRef]

[27] Ghitman J, Stan R, Iovu H (2017). Experimental contributions in the synthesis of PLGA nanoparticles with excellent properties for drug delivery: investigation of key parameters. Scientific Bulletin - University “Politehnica” of Bucharest, Series B; 79(2):101-112.

[28] Kreuter J (1994). Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet; 19:253-56. [CrossRef]

[29] Vyas SP, Khar RK (2002). Novel carrier systems. In: Vyas SP, Khar RK (eds) Targeted and controlled drug delivery. CBS Publishers and Distributors, New Delhi: pp 331 - 343.

[30] Modena MM, Rühle B, Burg TP, Wuttke S (2019). Nanoparticle characterization: What to Measure?. Adv Materials; 31(32):1901556. [CrossRef]

[31] Redhead HM, Davis SS, Illum L (2001). Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterization and in vivo evaluation. J Control Rel; 70(3):353-363. [CrossRef] [PubMed]

[32] Khanna VK (2012). Targeted delivery of nanomedicines. Int Scholar Res Not; 2012:571394. [CrossRef]

[33] Ray U (2018). What are the different types of nanoparticles?. https://www.azonano.com/article.aspx?ArticleID=4938 (accessed on 20 January 2021).

[34] Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, et al. (2020). Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules; 25(16):3731. [CrossRef] [PubMed]

[35] Rana V, Sharma R (2019). Recent advances in development of nano drug delivery. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S (eds.) Micro and nano technologies; Applications of Targeted Nano drug and delivery systems. Elsevier: pp 93-131. [CrossRef]

[36] Kumar R (2019). Lipid-based nanoparticles for drug-delivery systems. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S (eds.) Micro and nano technologies; Applications of Targeted Nano drug and delivery systems. Elsevier: pp 249-248. [CrossRef]

[37] Rawat MK, Jain A, Singh S (2011). Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci; 100(6):2366-78. [CrossRef] [PubMed]

[38] Samimi S, Maghsoudnia N, Eftekhari RB, Darkoosh F (2019). Lipid-based nanoparticles for drug delivery systems. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S (eds.) Micro and nano technologies; Characterization and Biology of Nanomaterials for Drug Delivery. Elsevier: pp 47-76. [CrossRef]

[39] Güven E (2020). Lipid-based nanoparticles in the treatment of erectile dysfunction. Int J Impot Res; 32:578–586. [CrossRef] [PubMed]

[40] Puri A, Loomis K, Smith B, Lee JH, et al. (2009). Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst; 26(6):523–580. [CrossRef] [PubMed]

[41] Maiti D, Tong X, Mou X, Yang K (2019). Carbon-based nanoparticles for biomedical applications: a recent study. Front Pharmacol; 9:1401. [CrossRef] [PubMed]

[42] Calandra P, Calogero G, Sinopoli A, Gucciardi PG (2010). Metal nanoparticles and carbon-based nanostructures as advanced materials for cathode application in dye-sensitized solar cells. Int J Photoenergy; 2010:109495. [CrossRef]

[43] Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019). An overview of active and passive targeting strategies to improve the nanocarrier efficiency to tumor sites. J Pharm Pharmacol; 71(8):1185-98. [CrossRef] [PubMed]

[44] Chonn A, Semple SC, Cullis PR (1992). Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem; 267(26):18759-65. [PubMed]

[45] Patel HM (1992). Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst; 9(1):39-90. [PubMed]

[46] Golombek SK, May JN, Theek B, Appold L, et al. (2018). Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev; 130:17-38. [CrossRef] [PubMed]

[47] Sagnella S, Drummond C (2012). Drug delivery: a nanomedicine approach. Australian Biochemist; 43(3):5-20.

[48] Gullotti E, Yeo Y (2009). Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol Pharmacol; 6(4):1041-51. [CrossRef] [PubMed]

[49] Damjanov I (2000). High-yield pathology. High yield series. Lippincott Williams and Wilkins, Pennsylvania, US.

[50] Bozzuto G, Molinari A (2015). Liposomes as nanomedical devices. Int J Nanomed; 10(1):975-99. [CrossRef] [PubMed]


Rights & Permissions

Copyright: © 2021 Hossain R et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.